Professors Lisa Schwartz and Steven Woloshin of the Center for Medicine
and the Media at The Dartmouth Institute for Health Policy and Clinical
Practice are raising alarms about a recent Food and Drug Administration
decision to approve a new dosage for the best-selling Alzheimer’s drug
Aricept (donepezil). The decision “breached the FDA’s own regulatory
standard” and has led to “incomplete and distorted messages” about the
drug, they warned in the latest British Medical Journal.
http://gooznews.com/?p=3744
